Characterization of a murine NKT cell tumor previously described as an acute myelogenous leukemia. Leuk Lymphoma 2002 Aug;43(8):1637-44
Date
10/29/2002Pubmed ID
12400607DOI
10.1080/1042819021000002974Scopus ID
2-s2.0-0036020969 (requires institutional sign-in at Scopus site) 20 CitationsAbstract
C1498 is an atypical myeloid leukemia that originated in a C57BL/6 mouse and has been used as a model for acute myelogenous leukemia. In studies of the immune response to C 1498, we found that this tumor contained mRNA encoding the canonical NKT cell receptor Vbeta8.2-Valpha14Jalpha281. Although cell-surface phenotypic analysis showed C1498 to be negative for NK1.1, it expressed several other molecules associated with NKT cell populations, such as DX5, CDld, CD69, CD44, CD45RB and B220. RT-PCR demonstrated that C1498 contained CD3epsilon mRNA transcripts, but message was not found for CD4, CD8alpha, or CD8beta. This indicates that C1498 falls within the double negative (CD4-CD8-) NKT cell lineage. RNase protection analysis showed that C1498 expressed mRNA for IL-2, IL-15, and macrophage migration inhibitory factor (MIF). These findings suggest that C1498 should be re-classified as a NKT cell leukemia with atypical myeloid features. It may, therefore, be a novel cell line in which to study NKT cell development and serve as a model for human NKT cell malignancies.
Author List
LaBelle JL, Truitt RLAuthor
Robert L. Truitt PhD Emeritus Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCD3 Complex
CD4 Antigens
CD8 Antigens
Cytokines
Immunophenotyping
Killer Cells, Natural
Leukemia, Myeloid, Acute
Mice
Mice, Inbred C57BL
RNA, Messenger
Receptors, Antigen, T-Cell
Receptors, Antigen, T-Cell, alpha-beta
Tumor Cells, Cultured
